| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Compass Therapeutics, Inc. | General Counsel | Common Stock | 171,000 | $884,070 | $5.17 | 02 Jan 2026 | Direct |
| Compass Therapeutics, Inc. | General Counsel | Stock Option (Right to Buy) | 720,000 | 02 Jan 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CMPX | Compass Therapeutics, Inc. | 02 Jan 2026 | 2 | +$775,500 | 4 | General Counsel | 05 Jan 2026, 16:32 |
| CMPX | Compass Therapeutics, Inc. | 07 Apr 2025 | 1 | +$30,800 | 4 | Gen Counsel & Corporate Sec | 08 Apr 2025, 09:30 |
| CMPX | Compass Therapeutics, Inc. | 11 Feb 2025 | 1 | $0 | 4 | Sr VP, Gen Counsel & Corp Sec | 13 Feb 2025, 17:09 |
| CMPX | Compass Therapeutics, Inc. | 13 Aug 2024 | 1 | $0 | 4 | Sr VP, Gen Counsel & Corp Sec | 14 Aug 2024, 08:49 |
| CMPX | Compass Therapeutics, Inc. | 01 Aug 2024 | 0 | $0 | 3 | Sr VP, Gen Counsel & Corp Sec | 09 Aug 2024, 16:07 |